세계의 유전자 침묵 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Gene Silencing Market was valued at USD 9.6 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 28.5 billion by 2034, driven by a rising global incidence of genetic diseases and rising demand for next-generation therapies. As more individuals are diagnosed with inherited conditions, the interest in treatments that modify or suppress disease-causing genes has accelerated. Healthcare systems are focusing on precision medicine, and gene silencing plays a crucial role in this shift, offering targeted therapeutic outcomes that conventional drugs cannot achieve. With improved biotechnological tools and stronger clinical pipelines, gene-based interventions are rapidly gaining traction among researchers and care providers.

The market has witnessed impressive technological strides, particularly with the adoption of advanced gene regulation methods. In 2024, the products segment held USD 7.7 billion, with continued expansion expected. Tools like CRISPR-Cas9, antisense oligonucleotides (ASOs), and RNA interference (RNAi) have proven vital in addressing genetic disorders at the molecular level. These technologies are unlocking new opportunities for targeted treatment, with ASOs showing promise in rare disease management and RNAi emerging as a platform for broader therapeutic applications.

Gene silencing market from the drug discovery and development segment captured 51% share in 2024 due to the growing use of RNAi and related technologies in research. Pharmaceutical and biotech companies are utilizing these tools to pinpoint disease-causing genes and streamline the early phases of drug development. The demand for gene-targeting platforms continues to grow as clinical trials for novel therapeutics expand across different therapeutic areas.

United States Gene Silencing Market is expected to reach USD 11.1 billion by 2034. The country's robust research infrastructure, backed by leading firms such as Thermo Fisher Scientific, Agilent Technologies, and Bio-Rad Laboratories, supports steady innovation in gene silencing treatments. Ongoing R&D investment and regulatory support also contribute to a favorable growth environment. The country remains a hub for clinical advancements and funding in genomic medicine.

Key players such as Merck KGaA, GenScript, Revvity Discovery, Santa Cruz Biotechnology, and New England Biolabs are strengthening their market presence through focused investments in RNAi and ASO platforms. These companies are expanding their portfolios with gene editing tools, custom oligo synthesis, and scalable delivery systems. Strategic partnerships with academic institutions and biotech startups help them stay ahead in clinical innovation. Firms invest in automation, AI-based gene target screening, and enhanced laboratory infrastructure to speed up research cycles. Continuous efforts to secure regulatory approvals and develop companion diagnostics are also central to competitiveness. By aligning product innovation with precision therapy trends, these companies capitalize on the growing need for targeted genetic treatments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of genetic disorders
    • 3.2.1.2 Increase demand for targeted therapies
    • 3.2.1.3 Advancements in delivery systems
    • 3.2.1.4 Growing investment in biotech and pharmaceutical research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory guidelines
    • 3.2.2.2 High cost and technical complexity
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (Cost of manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (Cost to consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 RNAi
    • 5.2.1.1 miRNA
    • 5.2.1.2 siRNA
    • 5.2.1.3 Other RNAi products
  • 5.2.2 CRISPR-Cas9
    • 5.2.2.1 CRISPR kits and reagents
    • 5.2.2.2 CRISPR libraries
    • 5.2.2.3 Other CRISPR-CAS 9 products
  • 5.2.3 Antisense oligonucleotides (ASOs)
  • 5.2.4 Other products
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery and development
  • 6.2.1 Neurology
  • 6.2.2 Oncology
  • 6.2.3 Infectious diseases
  • 6.2.4 Genetic disorders
  • 6.2.5 Other drug discoveries and developments
• 6.3 Therapeutics manufacturing
• 6.4 Agricultural applications
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Academic and research institutes
• 7.4 CROs and CMOs
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Agilent Technologies
• 9.2 Bio-Rad Laboratories
• 9.3 Cellecta
• 9.4 Danaher
• 9.5 GenScript
• 9.6 Merck KGaA
• 9.7 New England Biolabs
• 9.8 Qiagen
• 9.9 Revvity Discovery
• 9.10 Santa Cruz Botechnology
• 9.11 Thermo Fisher Scientific